表紙
市場調査レポート

アジア太平洋地域における眼科治療市場:高いアンメットニーズおよび穏やかな短期的見通し

Ophthalmology Therapeutics Market in Asia-Pacific to 2019 - High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity

発行 GBI Research 商品コード 290190
出版日 ページ情報 英文 72 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.16円で換算しております。
Back to Top
アジア太平洋地域における眼科治療市場:高いアンメットニーズおよび穏やかな短期的見通し Ophthalmology Therapeutics Market in Asia-Pacific to 2019 - High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity
出版日: 2013年10月31日 ページ情報: 英文 72 Pages
概要

アジア太平洋地域(インド・オーストラリア・中国・日本)のドライアイ症候群・緑内障市場は、2012年の24億米ドルとなり、今後はCAGR5%の成長が予測され、2019年までに33億米ドルへ達する見込みです。インドは予測期間を通してCAGR9.9%で最も急成長を示すと予測されています。2012年には、日本は同地域で最大の市場(市場額10億6,500万米ドル、市場シェア45%)となり、次に中国(市場額7億6,700万米ドル、市場シェア33%)が続きました。

当レポートでは、アジア太平洋地域における眼科治療市場の調査分析を行い、市場概要、主な市販薬、パイプライン製品、国別の市場予測、および主な契約動向などについてまとめ、概略下記の構成で取り上げております。

第1章 目次

第2章 アジア太平洋地域の眼科治療市場:イントロダクション

  • ドライアイ症候群
    • 分類
    • 症状
    • 病因
    • 病態生理学
    • 診断
    • 疫学
    • 予後
    • 治療の選択肢
  • 緑内障
    • 分類
    • 症状
    • 病因
    • 病態生理学
    • 診断
    • 疫学
    • 予後
    • 治療の選択肢

第3章 アジア太平洋地域の眼科治療市場:上市製品

  • ドライアイ症候群
  • 緑内障
  • 上市製品
    • Restasis
    • Systane
    • Diquas
    • Mucosta
    • Hyalein
    • Lumigan
    • Alphagan/Alphagan P

第4章 アジア太平洋地域の眼科治療市場:パイプライン分析

  • ドライアイ症候群のパイプライン
    • 全体的なパイプライン
    • パイプライン分析:分子タイプ別
    • パイプライン分析:作用機序別
  • 緑内障のパイプライン分析
    • 全体的なパイプライン
    • パイプライン分析:分子タイプ別
    • パイプライン分析:作用機序別
  • パイプラインにおける有望な候補薬
    • CF-101
    • MIM-D3
    • SAR-1118
    • DE-111

第5章 アジア太平洋地域の眼科治療市場:市場予測

  • アジア太平洋地域市場
    • 治療利用パターン
    • 治療の年間コスト
    • 市場規模
  • インド
    • 治療利用パターン
    • 治療の年間コスト
    • 市場規模
  • オーストラリア
    • 治療利用パターン
    • 治療の年間コスト
    • 市場規模
  • 中国
    • 治療利用パターン
    • 治療の年間コスト
    • 市場規模
  • 日本
    • 治療利用パターン
    • 治療の年間コスト
    • 市場規模
  • 促進因子・阻害因子
    • 促進因子
    • 阻害因子

第6章 アジア太平洋地域の眼科治療市場契約・戦略的合併

  • 契約分析
  • 主な共同開発契約
  • 主なライセンシング契約

第7章 アジア太平洋地域の眼科治療市場:付録

  • 全パイプライン薬:フェーズ別
  • 市場予測
  • 市場定義
  • 略語
  • ソース
  • 調査手法
  • 専門家の検証
  • 連絡先
  • 免責事項

図表リスト

目次
Product Code: GBIHC308MR

GBI Research has released its research, "Ophthalmology Therapeutics Market in Asia-Pacific to 2019 - High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity", which provides insights into two therapeutic indications in ophthalmology in Asia-Pacific (APAC) markets of India, China, Japan and Australia. The report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these two ophthalmology indications.

Scope

  • Disease overview and treatment usage patterns
  • Market size and forecast for glaucoma and DES in APAC market from 2012 to 2019
  • Major marketed products for the indications types covered
  • In-depth pipeline analysis for glaucoma and DES
  • Key drivers and restraints that have had and are expected to have a significant impact upon the market
  • Key licensing and co-development agreements in the ophthalmology market

Reasons to buy

  • The report will enhance your decision-making capability by allowing you to -
  • Align your product portfolio to the markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
  • Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the ophthalmology market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Abstract:

Ophthalmology Therapeutics Market in Asia-Pacific is Expected to Reach $3.3 Billion by 2019 with Modest Growth of 5%

The ophthalmology therapeutics market for Dry Eye Syndrome (DES) and glaucoma in four Asia-Pacific (APAC) countries, India, Australia, China and Japan, was worth $2.4 billion in 2012 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 5% to reach $3.3 billion by 2019.

The Indian market is expected to show the fastest growth over the forecast period with a CAGR of 9.9%. The other three markets are expected to see similar but slightly lower CAGRs, with China at 5%, Australia at 4.4%, and Japan at 4.2%. In 2012, Japan had the largest market in APAC with a value of $1,065m, or 45% of the total APAC ophthalmology market. The next largest market was China at $767m or 33% of the total APAC market. In the same year, the Indian market was valued at $427m, a share of 18%. Australia had the lowest market share at 4% with a market value of $95m.

Moderate Pipeline with Promising Drugs in Late Stages of Development Could Drive Market Expectations

The global ophthalmology pipeline is becoming increasingly innovative with a cluster of novel molecules in the early stages of development. The drug approval processes in many APAC countries, including Japan and China, require clinical trials to be run domestically in order to account for differences in drug metabolism between populations of different ethnicities. This can delay new drug launches but in the long term secures greater confidence in safety and efficacy profiles. There are currently five molecules in the Pre-registration stage of development that are expected to be granted approval within the forecast period. Two of these are indicted for DES and three for glaucoma. Nearly 36% of the pipeline for glaucoma and DES are molecules in the late stages of development (Phases II and III), and of these, 21 molecules (43%) are indicated for DES and 28 (57%) for glaucoma.

Some of the major factors driving the growth of the market are growing awareness of the importance of detecting ophthalmic diseases early, the availability of effective diagnostic tools, and an increase in the prevalence of both diseases. The expiration of blockbuster drug patents and the subsequent pressure from cheaper off-label products will be a key market restraint. A sizeable section of glaucoma patients require combination therapy - the use of additional agents to the treatment regimen - to control elevated intraocular pressure. The demand for combination products over single-ingredient formulations has risen, and they often improve patient compliance as the two drugs can be administered simultaneously.

Diquas (diquafosol tetrasodium), by Santen Pharmaceutical and Mucosta (rebamipide), by Otsuka Holdings were recently launched in Japan. These manufacturers must now focus on increasing diagnosis rates and growing their product's market share before looking at adding new therapies to the treatment scheme. The current DES pipeline in APAC is somewhat stagnant, as there are only three late-stage products expected to enter the market during the forecast period; Diquas will launch in China in 2013 and CF-101, in development by Can-Fite BioPharma, is expected to gain marketing approval in China by 2017 after approval in the US and Europe in 2014.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Ophthalmology Therapeutics Market in Asia-Pacific - Introduction

  • 2.1. Dry Eye Syndrome
    • 2.1.1. Classification
    • 2.1.2. Symptoms
    • 2.1.3. Etiology
    • 2.1.4. Pathophysiology
    • 2.1.5. Diagnosis
    • 2.1.6. Epidemiology
    • 2.1.7. Prognosis
    • 2.1.8. Treatment Options
  • 2.2. Glaucoma
    • 2.2.1. Classification
    • 2.2.2. Symptoms
    • 2.2.3. Etiology
    • 2.2.4. Pathophysiology
    • 2.2.5. Diagnosis
    • 2.2.6. Epidemiology
    • 2.2.7. Prognosis
    • 2.2.8. Treatment Options

3. Ophthalmology Therapeutics Market in Asia-Pacific - Marketed Products (Global)

  • 3.1. Dry Eye Syndrome
  • 3.2. Glaucoma
  • 3.3. Key Marketed Products
    • 3.3.1. Restasis
    • 3.3.2. Systane
    • 3.3.3. Diquas
    • 3.3.4. Mucosta
    • 3.3.5. Hyalein
    • 3.3.6. Lumigan
    • 3.3.7. Alphagan/Alphagan P

4. Ophthalmology Therapeutics Market in Asia-Pacific - Pipeline Analysis

  • 4.1. Dry Eye Syndrome Pipeline
    • 4.1.1. Overall Pipeline
    • 4.1.2. Pipeline Analysis by Molecule Type
    • 4.1.3. Pipeline Analysis by Mechanism of Action
  • 4.2. Glaucoma Pipeline
    • 4.2.1. Overall Pipeline
    • 4.2.2. Pipeline Analysis by Molecule Type
    • 4.2.3. Pipeline Analysis by Mechanism of Action
  • 4.3. Promising Drug Candidates in the Pipeline
    • 4.3.1. CF-101
    • 4.3.2. MIM-D3
    • 4.3.3. SAR-1118
    • 4.3.4. DE-111

5. Ophthalmology Therapeutics Market in Asia-Pacific - Market Forecast to 2018

  • 5.1. APAC Market
    • 5.1.1. Treatment Usage Patterns
    • 5.1.2. Annual Cost of Therapy
    • 5.1.3. Market Size
  • 5.2. India
    • 5.2.1. Treatment Usage Patterns
    • 5.2.2. Annual Cost of Therapy
    • 5.2.3. Market Size
  • 5.3. Australia
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. China
    • 5.4.1. Treatment Usage Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Japan
    • 5.5.1. Treatment Usage Patterns
    • 5.5.2. Annual Cost of Therapy
    • 5.5.3. Market Size
  • 5.6. Drivers and Barriers
    • 5.6.1. Drivers
    • 5.6.2. Barriers

6. Ophthalmology Therapeutics Market in Asia-Pacific - Deals and Strategic Consolidations (Global)

  • 6.1. Deals Analysis
  • 6.2. Major Co-Development Deals
    • 6.2.1. NicOx Signs Research Agreement with Pfizer
    • 6.2.2. Acucela Enters into Co-Development Agreement with Otsuka Pharma for Rebamipide
    • 6.2.3. Akorn Enters into Agreement with Azad Pharma
  • 6.3. Major Licensing Deals
    • 6.3.1. NicOx Enters into Worldwide Licensing Agreement with Bausch & Lomb
    • 6.3.2. Quark Pharma Amends Licensing Agreement with Pfizer for PF-655
    • 6.3.3. Asterand Enters into Licensing Agreement with Allergan

7. Ophthalmology Therapeutics Market in Asia-Pacific - Appendix

  • 7.1. All Pipeline Drugs by Phase
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. IND/CTA-filed
    • 7.1.4. Phase I
    • 7.1.5. Phase II
    • 7.1.6. Phase III
    • 7.1.7. Pre-registration
    • 7.1.8. Undisclosed
  • 7.2. Market Forecasts to 2019
    • 7.2.1. APAC
    • 7.2.2. Australia
    • 7.2.3. China
    • 7.2.4. India
    • 7.2.5. Japan
  • 7.3. Market Definitions
  • 7.4. Abbreviations
  • 7.5. Sources
  • 7.6. Research Methodology
    • 7.6.1. Coverage
    • 7.6.2. Secondary Research
    • 7.6.3. Primary Research
    • 7.6.4. Therapeutic Landscape
    • 7.6.5. Geographical Landscape
    • 7.6.6. Pipeline Analysis
  • 7.7. Expert Panel Validation
  • 7.8. Contact Us
  • 7.9. Disclaimer

List of Tables

  • Table 1: Ophthalmology Therapeutics Market, Categories of Dry Eye Treatment, 2011
  • Table 2: Ophthalmology Therapeutics Market, Treatment Recommendations for Dry Eye Syndrome by Disease Severity Level, 2011
  • Table 3: Ophthalmology Therapeutics Market, Medicines for Lowering Eye Pressure, 2013
  • Table 4: Ophthalmology Therapeutics Market, Global, Pipeline (Discovery), 2013
  • Table 5: Ophthalmology Therapeutics Market, Global, Pipeline (Preclinical), 2013
  • Table 6: Ophthalmology Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013
  • Table 7: Ophthalmology Therapeutics Market, Global, Pipeline (Phase I), 2013
  • Table 8: Ophthalmology Therapeutics Market, Global, Pipeline (Phase II), 2013
  • Table 9: Ophthalmology Therapeutics Market, Global, Pipeline (Phase III), 2013
  • Table 10: Ophthalmology Therapeutics Market, Global, Pipeline (Pre-registration), 2013
  • Table 11: Ophthalmology Therapeutics Market, Global, Pipeline (Undisclosed), 2012
  • Table 12: Ophthalmology Therapeutics Market APAC, Dry Eye Syndrome, Market Forecast, 2012-2019
  • Table 13: Ophthalmology Therapeutics Market, APAC, Glaucoma, Market Forecast, 2012-2019
  • Table 14: Ophthalmology Therapeutics Market, Australia, Dry Eye Syndrome, Market Forecast, 2012-2019
  • Table 15: Ophthalmology Therapeutics Market, Australia, Glaucoma, Market Forecast, 2012-2019
  • Table 16: Ophthalmology Therapeutics Market, China, Dry Eye Syndrome, Market Forecast, 2012-2019
  • Table 17: Ophthalmology Therapeutics Market, China, Glaucoma, Market Forecast, 2012-2019
  • Table 18: Ophthalmology Therapeutics Market, India, Dry Eye Syndrome, Market Forecast, 2012-2019
  • Table 19: Ophthalmology Therapeutics Market, India, Glaucoma, Market Forecast, 2012-2019
  • Table 20: Ophthalmology Therapeutics Market, Japan, Dry Eye Syndrome, Market Forecast, 2012-2019
  • Table 21: Ophthalmology Therapeutics Market, Japan, Glaucoma, Market Forecast, 2012-2019

List of Figures

  • Figure 1: Ophthalmology Therapeutics Market, Global, Sales of Restasis ($m), 2006-2012
  • Figure 2: Ophthalmology Therapeutics Market, Global, Sales of Diquas ($m), 2010-2012
  • Figure 3: Ophthalmology Therapeutics Market, Global, Sales of Mucosta ($m), 2009-2012
  • Figure 4: Ophthalmology Therapeutics Market, Global, Sales of Hyalein ($m), 2009-2012
  • Figure 5: Ophthalmology Therapeutics Market, Global, Sales of Lumigan ($m), 2006-2012
  • Figure 6: Ophthalmology Therapeutics Market, Global, Sales of Alphagan/Alphagan P ($m), 2006-2012
  • Figure 7: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline (%), 2013
  • Figure 8: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Molecule Type, 2013
  • Figure 9: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Mechanism of Action, 2012
  • Figure 10: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline, 2013
  • Figure 11: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Molecule Type, 2013
  • Figure 12: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Mechanism of Action, 2013
  • Figure 13: Ophthalmology Therapeutics Market, APAC, Market Size ($m), 2012-2019
  • Figure 14: Ophthalmology Therapeutics Market, India, Market Size ($m), 2012-2019
  • Figure 15: Ophthalmology Therapeutics Market, Australia, Market Size ($m), 2012-2019
  • Figure 16: Ophthalmology Therapeutics Market, China, Market Size ($m), 2012-2019
  • Figure 17: Ophthalmology Therapeutics Market, Japan, Market Size ($m), 2012-2019
  • Figure 18: Ophthalmology Therapeutics Market, Global, Deals, 2006-2013
  • Figure 19: Ophthalmology Therapeutics Market, Global, Co-Development Deals, 2006-2013
  • Figure 20: Ophthalmology Therapeutics Market, Global, Licensing Deals, 2006-2013
  • Figure 21: GBI Research Market Forecasting Model
Back to Top